Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Aubagio is a prescription medicine containing teriflunomide, a pyrimidine synthesis inhibitor. It is approved for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Aubagio comes as 7 mg and 14 mg tablets taken once daily with or without food.
read more about aubagio ...The exact therapeutic mechanism in multiple sclerosis is unknown. Teriflunomide inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in de novo pyrimidine synthesis. This action reduces pyrimidine production needed by rapidly dividing cells and is associated with reduced proliferation of activated lymphocytes involved in inflammatory activity in multiple sclerosis.
Aubagio is approved for relapsing forms of multiple sclerosis in adults. These forms include clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive disease. It is not approved for pediatric patients under current U.S. labeling. Treatment selection considers liver status, pregnancy potential, infection status, blood counts, blood pressure, and other medicines.
The recommended dose is 7 mg or 14 mg by mouth once daily, with or without food. Blood tests assess liver enzymes before treatment and monthly for the first six months. A complete blood count and tuberculosis screening are completed before treatment. Cholestyramine or activated charcoal can speed removal of teriflunomide from the body when rapid elimination is needed.
Aubagio carries boxed warnings for serious liver injury and fetal harm. Other concerns include low white blood cell counts, serious infections, severe skin reactions, DRESS, peripheral neuropathy, increased blood pressure, respiratory effects, and impaired wound healing. Pregnancy is excluded before treatment in females of reproductive potential, and liver tests require close monitoring.
Aubagio treats relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Aubagio is taken once daily at a dose of 7 mg or 14 mg, with or without food.
Yes. Liver enzymes are checked before treatment and at least monthly for the first six months.
Yes. Teriflunomide clears slowly, so cholestyramine or activated charcoal can be used when faster elimination is needed.
AUBAGIO (teriflunomide) Medication Guide. https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=4650d12c-b9c8-4525-b07f-a2d773eca155. Date Accessed September 14, 2026.
AUBAGIO (teriflunomide) Prescribing Information. https://products.sanofi.us/aubagio/aubagio.pdf. Date Accessed September 14, 2026.
DailyMed - AUBAGIO (teriflunomide) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4650d12c-b9c8-4525-b07f-a2d773eca155. Date Accessed September 14, 2026.
FDALabel - AUBAGIO (teriflunomide). https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/110851. Date Accessed September 14, 2026.
Teriflunomide. MedlinePlus. https://medlineplus.gov/druginfo/meds/a613010.html. Date Accessed September 14, 2026.